Medical Writing Good Pharma Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles

Volume 22, Issue 4 - Good Pharma

Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles


There are persistent concerns about the influence of the pharmaceutical and device industries on the medical literature, and particularly on the reporting of clinical trials, which can include the distortion of the true evidence base of medical interventions and overestimation of the clinical benefit of a drug used to treat patients.

Download the full article


  1. Lemmens T. Leopards in the temple: restoring scientific integrity to the commercialized research scene. JL Med Ethics 2004;32:641–657.
  2. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Med 2009;6:e23. Available from:
  3. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Soc Stud Sci 2009;39:171–198.
  4. Matheson A. Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 2008;3:355–382.
  5. Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 2003;183:22–27.
  6. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800–1812.
  7. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold ‘HRT.’ PLoS Med 2010;7:e1000335 Available from:
  8. Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: Selective reporting of Study 329. The International Journal of Risk and Safety in Medicine 2008;20:183–183.
  9. Johnson KR, Lassere MND. Guest authorship, mortality reporting, and integrity in rofecoxib studies. JAMA 2008;300:900; author reply 904–906.
  10. Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998;280:222–224.
  11. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138 Available from:
  12. Moffatt B, Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 2007;50:18–31.
  13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, et al. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007;4:e19. Available from:
  14. United States Senate Committee on Finance Ghostwriting in medical literature minority staff report, 111th Congress, Sen. Charles E. Grassley, Ranking Member. 2010. p.
  15. Biagioli M. Rights or rewards? Changing contexts and definitions of scientific authorship. Journal of College and University Law 2000;27:83–108.
  16. Edmond G. Judging the scientific and medical literature: some legal implications of changes to biomedical research and publication. Oxford Journal of Legal Studies 2008;28:523–561.
  17. Daubert v. Merrell Dow Pharmaceuticals. 509 U.S. 579 1993.
  18. Lexchin J. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167–1170.
  19. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454–465.
  20. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, et al. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int 2010;107:279–285.
  21. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, et al. The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int 2010;107:295–301.
  22. Caplovitz A. Turning medicine into snake oil, how pharmaceutical marketers put patients at risk. Boston and Washington (D.C.): U.S. PIRG; 2006 .
  23. International Committee of Medical Journal Uniform requirements for manuscripts submitted to biomedical journals: ethical considerations in the conduct and reporting of research: authorship and contributorship. 2009. Available from:
  24. World Association of Medical. Ghost writing initiated by commercial companies. 2005. Available from:
  25. Committee on Publication Ethics (COPE). COPE code of conduct. 2011 Available from:
  26. The PLoS Medicine Editors. Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med 2009;6:e1000156 Available from:
  27. McHenry LB, Jureidini J. Industry-sponsored ghostwriting in clinical trial reporting: a case study. Accountability in Research 2008;15(3):152–167.
  28. Smith R. Lapses at the New England journal of medicine. J R Soc Med 2006;99:380–382.
  29. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 2007;4:e286. Available from:
  30. Moffat B. Responsible authorship: why researchers must forgo honorary authorship. Account Res 2011;18(2):76–90.
  31. Baty P. Academic made ‘untrue’ declaration about ‘full access’ to research material, GMC finds. Times Higher Education. 10 November 2009. Available from:
  32. Irvine D. A short history of the General Medical Council. Medical Education 2006;40(3):202–211. Available from:
  33. Picard A. Does self-regulation work for the medical profession? The Globe and Mail, 19 August 2007. Available from:
  34. Lacasse JR, Leo J. Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research. BMC Research Notes 2011;4:27.
  35. Rakes v. Life Investors Ins. Co. of America, 582 F.3d 886 (8th Cir 2009).
  36. R. v. Théroux, [1993] 2 S.C.R. 5 [Canada]; Magill v. Magill, (2006) 231 A.L.R. 277 (HC) [Australia]; Barlow Clowes International Ltd v Eurotrust International Ltd (2005) [United Kingdom]; Commissioner of Customs (Preventive) v. Aafloat Textiles (I) P. Ltd. 2009 (235) E.L.T. 587 (S.C.) [India].
  37. Edmond G. Supersizing Daubert science for litigation and its implications for legal practice and scientific research. Villanova Law Review 2007;52:857–924.
  38. 31 U.S.C. 1 3729.
  39. Strom ex rel. U.S. v. Scios, Inc., 676 F. Supp.2d 884 (N.D. Cal. 2009).
  40. 18 U.S.C. 1 2.
  41. 18 U.S.C. 11 1961–62.
  42. Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479 1985.
  43. Am. Nat'l Bank & Trust Co. v. Haroco, Inc., 473 U.S. 606 1985.
  44. Holmes v. Sec. Investor Prot. Corp., 503 U.S. 258 1992.
  45. Bridge v. Phoenix Bond & Indemnity Co., 128 S. Ct. 2131 2008.
  46. R. v. Stoltz 84 C.C.C. (3d) 422 (B.C.C.A.) [Canada]; S.P. Chengalvaraya Naidu v. Jagannath, [1994] 1 S.C.C. 1 [India]; McDonald v. McDonald (1965), 39 A.J.L.R. 179 (H.C.) [Australia]; Ul-Haq v. Shah [2010], 1 All E.R. 73 (C.A.) [U.K.] 1993.
  47. Johnson v Bell, 605 F.3d 333 (6th Cir 2010).
  48. Hazel-Atlas Glass Co. v. Hartford-Empire Co., 322 U.S. 238 1944.
  49. Hatch v. Ooms, 69 F. Supp. 788 (D.D.C.1947), rev'd sub nom. Dorsey v. Kingsland, 173 F.2d 405 (D.C. Cir. 1949), rev'd, 338 U.S. 318 (1949).



Good pharma
Message from the President
Transparency and the healthcare industry: The Sun is shining
Sunshine spreading across the Atlantic and over Europe
Bad karma
If a misinformed voice speaks out in the wilderness and no one refutes it, does it make a sound? A call to advocacy
The Big Pharma conspiracy theory
Editorial: Pharmaism
Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles
A decade of change: A new ISMPP has arrived
Selling evidence over the counter: Do community pharmacists engage with evidence-based medicine?
Good regulatory practice and the role(s) of a regulatory affairs professional
Profile: An interview with Dr Gustavo A. Silva on the concept of public health in medical writing and translation
AuthorAID: An international service and chance to serve
India as a hub for ethical and evidence-based medical communications
Providing value for medicines in older people
In the Bookstores
Journal Watch
The Webscout
Regulatory Writing
Medical Communications
Manuscript Writing
Out On Our Own
The Light Stuff


The Write Stuff Archive Contact Instructions for Authors Article Template (Word) Journal Policies

Editoral Board


Raquel Billiones


Evguenia Alechine

Jonathan Pitt

Managing Editor

Victoria White

Associate Editors

Anuradha Alahari

Jennifer Bell

Nicole Bezuidenhout

Claire Chang

Barbara Grossman

Sarah Milner

John Plant

Sampoorna Rappaz

Amy Whereat

Section Editors

Daniela Kamir


Jennifer Bell


Nicole Bezuidenhout 

Digital Communication

Somsuvro Basu

EMWA News 

Ana Sofia Correia 

Gained in Translation

Ivana Turek

Getting Your Foot in the Door

Wendy Kingdom / Amy Whereat

Good Writing Practice

Alison McIntosh 

In the Bookstores

Maria Kołtowska-Häggström

Lingua Franca and Beyond

Maddy Dyer


Lisa Chamberlain-James

Medical Communications/Writing for Patients

Payal Bhatia

Medical Devices

Evguenia Alechine

My First Medical Writing

Anuradha Alahari

News from the EMA

Adriana Rocha


Tiziana von Bruchhausen


Clare ChangZuo Yen Lee 

Regulatory Matters

Sam Hamilton

Regulatory Public Disclosure

Claire Gudex

Teaching Medical Writing

Louisa Ludwig-Begall / Sarah Kabani

The Crofter: Sustainable Communications

Louisa Marcombes

Veterinary Writing

Editors Emeritus

Elise Langdon-Neuner

Phil Leventhal

Layout Designer

Chris Monk